P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Forward Looking Statements

Any

statements

in

this

presentation

about

future

expectations,

plans

and

prospects

for

the

Company,

including

statements

containing

the

words

"believes,"

"anticipates,"

"plans,"

"expects,"

and

similar

expressions,

constitute

forward

looking

statements,

which

are

subject

to

the

safe

harbor

for

such

statements

in

the

Private

Securities

Litigation

Reform

Act

of

1995.

Future

events

could

cause

actual

results

to

differ

materially

from

those

indicated

by

such

statements.

Reference

is

made

to

the

factors

discussed

in

the

“Management

Discussion

and

Analysis"

and

"Risk

Factors"

sections

of

the

Company's

most

recent

quarterly

or

annual

report

filed

with

the

Securities

and

Exchange

Commission.

The

forward-looking

statements

herein

represent

the

Company's

views

as

of

the

date

of

this

presentation

and

should

not

be

relied

upon

to

represent

the

Company's

views

as

of

a

subsequent

date.

While

the

Company

anticipates

that

subsequent

events

may

cause

the

Company's

views

to

change,

the

Company

disclaims

any

obligation

to

update

such

forward-looking

statements.

2

*

*

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Mission

Advancing Drugs Through

Glycoscience

®

3

*

*

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Key Investment Points

•

Clinical stage pharmaceutical company

–

Completed Phase I/II cancer trials w/ DAVANAT

®

–

Stabilized 35% of end stage patients: 2-13 months

–

Two ongoing Phase II front line trials

•

DAVANAT

®

increased the half life of 5-FU

8 fold with no increase in toxicity

•

DAVANAT

®

/5-FU model can be applied to

other chemotherapy agents

4

Clinical Trial Program

–

Completed Phase I/II cancer trials w/ DAVANAT

®

–

Stabilized 35% of end stage patients: 2-13 months

–

Two ongoing Phase II front line trials

*

*

5

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Phase I/II End Stage Cancer Trials

Summary

•

35% stabilized at the highest dose level

•

Maximum Tolerated Dose & Dose

Limiting Toxicity not reached

•

DAVANAT

®

significantly increased half

life of 5-FU with no increase in toxicity

6

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Phase I Clinical Trial Summary

•

DAVANAT

®

was well tolerated

•

Maximum Tolerated Dose and Dose Limiting Toxicity

of DAVANAT

®

not reached

–

DAVANAT

280

mg/m²

recommended

Phase

II

dose

•

Pharmacokinetics

–

Half life of 5-FU alone is 6-22 minutes

–

Half life of 5-FU with DAVANAT

®

is 28-137 minutes

–

No increase in 5-FU toxicity w/ increased exposure

•

Stable disease in 14 of 26 efficacy evaluable patients

–

7/10 patients stabilized at the highest DAVANAT

®

dose level

7

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

SD

Stable Disease

PD

Progressive Disease

NM

Non-Measurable Disease

Cycles Completed

Dose, cycle 2

/m2

1+2

3

4

5

6

7

1001

PD

1002

SD

2001

Hepatocellular

PD

2002

Hepatocellular

SD

3001

PD

3002

SD

3004

PD

3003

PD

5001

SD

2004

SD

3005

PD

4001

PD

4002

Colorectal

PD

3006

Prostate

NM

2005

Colorectal

SD

5003

Colorectal (appendix)

NM

5004

SD

4003

PD

2007

Spindle Cell

PD

5005

Pancreatic

SD

2008

Colorectal

SD

2009

Colorectal

SD

5006

Billiary

SD

2010

Colorectal (cecal)

SD

2014

Breast

SD

2016

Hepatic

PD

2018

Cholangiocarcinoma

SD

5008

Pancreatic

PD

280 mg

150 mg

Patient

Number

Tumor Type

Outcome, end

of cycle 2

(RECIST)

C   Y   C   L   E   S

Colorectal

Colorectal

210 mg

30 mg

60 mg

Colorectal

100 mg

Colorectal

Phase l Patient Summary:

Stabilized 70% at Highest Dose Level

8

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Phase II Colorectal Cancer Trial Summary

•

Trial conducted with end-stage patients

•

Anti-tumor activity was seen with

DAVANAT

®

/5-FU

–

1 patient experienced Partial Response

–

6 patients stabilized

•

No increase in 5-FU toxicity w/ increased

exposure

9

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

DAVANAT

®

/5-FU

Enrolling Phase II Colorectal Cancer Trial

•

Indication:

First-line treatment of patients who are

unable to tolerate irinotecan or oxaliplatin

•

Regimen:

DAVANAT

®

/5-FU, Leucovorin,

AVASTIN

®

–

Repeat cycles every 2 weeks to disease progression or

toxicity

•

Objectives:

Complete/Partial Response

–

Stable Disease; Progression Free Survival; Safety;

Quality of Life

•

Design:

Multi-center, open label study

–

Simon Optimal 2-stage design

•

Patients:

Up to 50 patients  

–

Begin enrolling/ dosing patients in Q4 2006

10

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

DAVANAT

®

/5-FU

Enrolling Phase II Biliary Cancer Trial

•

Indication:

First line treatment of patients with biliary

tract cancer

•

Regimen:

DAVANAT

®

(280

mg/m²)

+

5-FU

(600

mg/m²)

IV

daily

x

4

days

–

Repeat cycles every 28 days to disease

progression or toxicity

•

Objectives:

Complete/Partial Response     

–

Stable Disease; Progression Free Survival; Safety;

Quality of Life

•

Design:

Multi-center, open label study

–

Simon Optimal 2-stage design

•

Patients:

Up to 35

–

Begin enrolling/dosing patients in Q4 2006

11

DAVANAT

®

Increases the

Half Life of 5-FU, 8 Fold

with No Increase in

Toxicity

*

*

12

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

DAVANAT

®

Increases Half Life

of 5-FU in Patients, 8 times

5-FU / DAVANAT –

Day 4

5-FU / DAVANAT –

Day 1

5-FU –

Historical

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

5-FU

in

the

presence

of

DAVANAT

®

Does

Not

Change

Key

Toxicity

Markers

0

10

20

30

40

0

10

20

30

40

AUC

Hematocrit

Hemoglobin

Red blood cells

White blood cells

Platelets

The DAVANAT

®

/5-FU Model

Can Be Applied To

Increasing Efficacy/

Decreasing Toxicity of Other

Chemotherapy Agents

15

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

DAVANAT

®

with another Chemotherapy Agent

100

1000

10000

0

10

20

30

40

Time post implanatation (Days)

Control

IR40/DAV6

IR40/DAV30

IR40/DAV120

16

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Mechanism of Action:

Targeting Lectins on Cancer Cells

•

DAVANAT

®

binds to lectins

•

Galectins are a type of lectin that are over-

expressed on cancer cells

•

Galectins affect cell development,

differentiation, apoptosis and tumor

metastasis

17

P R O           P H A R M A C E U T I C A L S ,  I N C.

A

D

V

A

N

C

I

N

G

D

R

U

G

S

T

H

R

O

U

G

H

G

L

Y

C

O

S

C

I

E

N

C

E

®

Amex: P R W

Key Investment Points

•

Clinical stage pharmaceutical company

–

Completed Phase I/II cancer trials w/ DAVANAT

®

–

Stabilized 35% of end stage patients: 2-13 months

–

Two ongoing Phase II front line trials

•

DAVANAT

®

increased the half life of 5-FU

8 fold with no increase in toxicity

•

DAVANAT

®

/5-FU model can be applied to

other chemotherapy agents

18